



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72

(51) International Patent Classification (IPC):
G01N 33/566 ^(2006.01) **C12M 1/34** ^(2006.01)
C40B 30/04 ^(2006.01) **C40B 60/12** ^(2006.01)
G01N 33/573 ^(2006.01) **G01N 33/68** ^(2006.01)

(48) Corrigendum issued on:
24.08.2022 Bulletin 2022/34

(52) Cooperative Patent Classification (CPC):
G01N 33/6893; G01N 33/68; G16B 40/00;
G16B 40/20; G16H 50/20; G01N 2333/4745;
G01N 2333/8146; G01N 2800/347; G01N 2800/50;
Y02A 90/10

(45) Date of publication and mention
of the grant of the patent:
01.06.2022 Bulletin 2022/22

(21) Application number: **20162229.7**

(22) Date of filing: **16.01.2014**

(54) **METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE**

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR DIAGNOSE UND PROGNOSE VON
NIERENLÄSION UND NIERENINSUFFIZIENZ

PROCÉDÉS ET COMPOSITIONS POUR LE DIAGNOSTIC ET LE PRONOSTIC DE LÉSIONS
RÉNALES ET D'INSUFFISANCE RÉNALE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **17.01.2013 US 201361753723 P**

(43) Date of publication of application:
04.11.2020 Bulletin 2020/45

(60) Divisional application:
22176536.5

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
18157605.9 / 3 361 255
14740960.1 / 2 946 211

(73) Proprietor: **Astute Medical, Inc.**
San Diego, CA 92121 (US)

(72) Inventors:
• **Anderberg, Joseph**
Encinitas, CA California 92024 (US)

- **Gray, Jeff**
deceased (US)
- **McPherson, Paul**
Encinitas, CA California 92024 (US)
- **Nakamura, Kevin**
Encinitas, CA 92024 (US)
- **Kampf, James Patrick**
San Diego, CA California 92130 (US)

(74) Representative: **Wilding, James Roger et al**
Mathys & Squire
The Shard
32 London Bridge Street
London SE1 9SG (GB)

(56) References cited:
WO-A1-2011/035323 US-A1- 2012 283 128

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- **CARON ET AL: "Ischemia injury alters endothelial cell properties of kidney cortex: Stimulation of MMP-9", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US, vol. 310, no. 1, 15 October 2005 (2005-10-15), pages 105-116, XP005093311, ISSN: 0014-4827, DOI: 10.1016/J.YEXCR.2005.07.004**
- **QIANG YAN ET AL: "Expression of MMP-2 and TIMP-1 in Renal Tissue of Patients with Chronic Active Antibody-mediated Renal Graft Rejection", DIAGNOSTIC PATHOLOGY, BIOMED CENTRAL LTD, LO, vol. 7, no. 1, 12 October 2012 (2012-10-12), page 141, XP021137264, ISSN: 1746-1596, DOI: 10.1186/1746-1596-7-141**
- **MAZANOWSKA O ET AL: "Imbalance of Metalloproteinase/Tissue Inhibitors of Metalloproteinase System in Renal Transplant Recipients With Chronic Allograft Injury", TRANSPLANTATION PROCEEDINGS, vol. 43, no. 8, 2011, pages 3000-3003, XP028311963, ISSN: 0041-1345, DOI: 10.1016/J.TRANSProceed.2011.08.012 [retrieved on 2011-08-22]**